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Background: Notch and Hedgehog signaling have been implicated in the pathogenesis and stem-like characteristics
of glioblastomas, and inhibitors of the pathways have been suggested as new therapies for these aggressive tumors.
It has also been reported that targeting both pathways simultaneously can be advantageous in treating glioblastoma
neurospheres, but this is difficult to achieve in vivo using multiple agents. Since arsenic trioxide has been shown to
inhibit both Notch and Hedgehog in some solid tumors, we examined its effects on these pathways and on stem cell
phenotype in glioblastoma.
Results: We found that arsenic trioxide suppresses proliferation and promotes apoptosis in three stem-like glioblastoma
neurospheres lines, while inhibiting Notch and Hedgehog target genes. Importantly, arsenic trioxide markedly reduced
clonogenic capacity of the tumor neurospheres, and the stem-like CD133-positive fraction was also diminished along
with expression of the stem cell markers SOX2 and CD133.
Conclusions: Our results suggest that arsenic trioxide may be effective in targeting stem-like glioblastoma cells in
patients by inhibiting Notch and Hedgehog activity.Introduction
Glioblastoma (GBM) are the most common primary
adult brain malignancy, and despite some advances in
therapeutic options survival remains dismal. One reason
suggested for the deadliness of this disease is the pres-
ence of treatment-resistant stem-like cancer cells [1-6].
While conventional therapies are thought to target much
of the tumor, it is believed that stem-like neoplastic cells
survive and go on to regenerate the lesion. We therefore
need new therapies targeting these cancer stem cells
(CSC) in glioma.
Notch and Hedgehog signaling have been implicated
in the survival of CSC in GBM by our group and others,
and single agent therapies targeting either pathway have
yielded promising results [7-17]. However, single therap-
ies often allow resistance to develop in tumor cells, sug-
gesting that several pathways will need to be targeted
simultaneously if we are to eradicate GBM in patients.* Correspondence: ceberha@jhmi.edu
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unless otherwise stated.Our group recently identified one mechanism of cellular
resistance to Notch pathway inhibition in GBM: direct
upregulation of the Hedgehog pathway through a novel
cross talk mechanism. This involved constitutive sup-
pression of Hedgehog activity by direct binding of the
Notch mediator HES1 to the GLI promoter [18]. While
dual agent therapy with separate compounds targeting
both Notch and Hedgehog was able to overcome this
problematic therapeutic resistance, toxicity and other
issues limit the in vivo use of the specific agents tested
in our prior study. We have therefore now investigated
the potential of a single compound, arsenic trioxide
(ATO), to target both Notch and Hedgehog signaling in
stem-like glioma cells.
Arsenic trioxide was first used in the treatment of acute
promyelocytic leukemia (APL) in China, where one of the
potential mechanisms of action involved induction of dif-
ferentiation of leukemic cells [19,20]. ATO has since been
FDA approved for treatment of APL patients for which
ATRA failed to work [21]. The effects of ATO were subse-
quently examined in other tumor types, including multiple
myeloma, glioma, neuroblastoma, esophageal carcinoma
and prostate cancer, and it has been found to be effica-
cious in many of these as well [22-27].d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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but in many tumors it is thought to function via regula-
tion of various developmental pathways important in
cancer. In APL for example, ATO inhibits the oncogenic
fusion protein promyelocytic leukemia-retinoic acid re-
ceptor α (PML-RAR) [28]. In other tumors such as basal
cell carcinoma, ATO is believed to exert its effects by
inhibiting the Hedgehog signaling pathway [29]. Finally,
in one report using glioma cells grown adherently, ATO
was shown to target Notch signaling [30].
A number of studies have looked at the anti-growth
effects of ATO in gliomas, however all but one were
done using adherent glioma lines grown in high serum
[27,30-40]. It has been suggested that glioma cells grown
under these conditions are poor models in which to
address CSC related issues [41]. We therefore used
several serum-free glioblastoma neurosphere cultures to
examine the effects of ATO on the growth and survival
of stem-like tumors cells, as well as its effects on key
developmental pathways such as Notch and Hedgehog.
We found that ATO inhibits both of these pathways,
along with growth, clonogenicity and stem-cell charac-
teristics in the GBM neurospheres.
Material and methods
Cell culture condition and drug preparation
HSR-GBM1, 040622 and 040821 neurosphere lines were
kind gifts from Dr. Angelo Vescovi. They include two
temozolomide resistant neurosphere cultures (HSR-
GBM1 and 040622) and one temozolomide sensitive
one (040821) [42]. None are mutated at the IDH1
locus, and HSR-GBM1 and 040622 lack alterations in
p53, while 040821 cells have a mutation in p53 exon 7
resulting in substitution of serine for proline in amino
acid 278. All are completely methylated at the MGMT
locus. Prior studies have shown that all three lines are
sensitive to pharmacological Notch blockade [7,18,42],
while Hedgehog inhibition has been shown to inhibit
growth and clonogenicity of HSR-GBM1 and 040622
(HSR-GBM2) cells [8,18]. GBM neurospheres were
maintained in Neurocult Complete Medium supple-
mented with human epidermal growth factor and hu-
man fibroblast growth factor (Peprotech, Rocky Hill,
NJ). Arsenic Trioxide (ATO) powder (Sigma, St Louis,
Mo-Aldrich) was dissolved in 1 mM sodium hydroxide.
Cell number and viability were assessed using the
hemocytometer and trypan blue.
Determination of cell growth
We performed MTS assays to determine growth in
viable cell mass. Cells were seeded into 96-well plates at a
density of 5000 per well in 100 μl of medium. Cells were
then treated with concentrations of arsenic trioxide (ATO)
ranging from 0 μM to 5 μM and incubated in 5% CO2 at37°C. For the MTS readings, 20 μl of MTS solution was
added to each well at 24, 48 and 72 hours post plating and
incubated for 1 hour. After that optical density was mea-
sured by spectrophotometer. The experiments were re-
peated at least three times for each cell line.
Cell proliferation assay
BrdU assay was performed to determine proliferation.
Cells were treated with concentrations of ATO ranging
from 0 μM to 5 μM for 72 hours, and then cytospun
onto slides. They were then fixed with 4% formaldehyde
in PBS for 15 minutes, and permeabilized with 0.1%
Triton/PBST for 15 minutes. Cellular proteins were then
denatured with 2 N HCL, washed with PBST (PBS
Tween-20), blocked with 5%NGS/PBST for 15 minutes
and then incubated in primary antibody against BrdU
(Sigma, B2531). Anti-BrdU antibody was used per the
manufacturer’s instruction at 1:500 dilution. After washing
3 times with PBST, cells were incubated for 45 minutes in
the dark with the appropriate cy-3 conjugated secondary
antibody. Cells were then counterstained with 4’,6-diami-
dino-2-phenylindole (DAPI), mounted with Vectashield
(Vector Laboratories), and visualized and pictures taken
by fluorescence microscopy.
Western blot analysis
Proteins were extracted from HSR-GBM1, 040622 and
040821 treated with ATO for 72 hours. The cells were
lysed, sonicated until clear, and then centrifuged at 4°C
and 15000 rpm for 10 min to remove cell debris. Subse-
quently, protein separation was performed on a 4-12%
SDS-polyacrylamide gel by electrophoresis, and then
transferred onto PVDF membranes. Membranes were
then probed with primary antibodies overnight.
Cell cycle analyses
Cells were plated in 6-well plates at a density of 1.5 ×
105-2.5 × 105 cells per well and treated with ATO ran-
ging from 0 μM to 5 μM for 72 hours. Cells were then
fixed with 70% ethanol for at least 12 hours and stained
with Guava Cell Cycle Reagent (Millipore, Billerica,
MA). Cell cycle analyses were performed using the
Guava PCA machine.
Clonogenic assays
HSR-GBM1, 040622 and 040821 neurospheres were
treated with concentrations of ATO ranging between
0 μM and 5 μM for 72 hours. Neurospheres were then
mechanically dissociated into single cells. 20000 viable
cells were counted and plated in fresh media containing
methylcellulose in 6-well plates. No ATO was present
during this growth phase of the clonogenic assay. Pic-
tures of colonies were taken after 10–12 days. 2–3 wells
were plated per cell line and 3–4 separate fields were
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diameter of each colony and its corresponding right
angle diameter and the measurements averaged. The
number of colonies that have an average diameter
above 100 μM were then counted for each field and
graphed.
Flow cytometric analyses
For CD133 flow cytometric analyses, neurospheres
were treated with 0 μM-5 μM ATO for 24 hours and
then collected, dissociated, and stained for CD133.
Flow cytometry was then performed as previously de-
scribed [43]. In brief, a PE-conjugated CD133 antibody
(Miltenyl Biotec, Auburn, CA), was incubated on ice
with the dissociated neurosphere cells for 10 minutes,
protected from light. Cells were then washed and re-
suspended in 500 μl of DMEM/F12 without phenol red
containing 1% BSA. Cells incubated with isotype con-
trol in parallel were used to set the gates. Cells with
PE-readings above isotype control were considered
CD133-positive.
Quantitative real-time PCR analyses
HSR-GBM1, 040622 and 040821 were collected after
treatment with 0 μM-5 μM ATO for 24 hours. RNA was
then extracted, reversed transcribed, and cDNA levels
analyzed by quantitative real-time PCR analysis per-
formed in triplicate with SYBR Green reagents (Bio-Rad,
Hercules, CA). Standard curves were used to determine
expression levels and all values were normalized to be
ta-actin. Statistical comparisons are between multiple
experiments each with triplicate technical replicates. Pri-
mer sequences were as follows: HES1 forward 5′-GTC
AAG CAC CTC CGGAAC-3′; HES1 reverse 5′-CGT
TCA TGC ACT CGC TGA-3′; HEY1 forward 5′-TCT
GAG CTG AGA AGG CTG GT-3′; HEY1 reverse
5′-CGA AAT CCC AAACTC CGA TA-3′; PTCH1B for-
ward 5′-GAC GCC GCC TTC GCT CTG-3′; PTCH1B
reverse 5′-GCC CAC AAC CAA GAA CTT GCC-3′;
N-Myc forward 5′-CGACCACAAGGCCCTCAGTA -3′;
N-Myc reverse 5′-CAGCCTTGGTGTTGGAGGAG-3′
[44]; GLI2 forward 5′-AATCGCACCCACTCCAAC-3′;
GLI2 reverse 5′-TGGGGTCTGTGTATCTCTTGG-3′;
Human actin- β forward – 5′-CCCAGCACAATGAA
GATCAA-3′; and human actin-β reverse: 5′-GATCCA
CACGGAGTACTTG- 3′.
Statistical analyses
Statistical significance was evaluated using unpaired,
two-tailed Student’s t-test. P-values <0.05 were consid-
ered statistically significant. Unless otherwise noted,
error bars represent standard error of the mean. All
statistical tests were performed using the GraphPad
Prism 5 software (GraphPad Software, La Jolla, CA).Results
ATO inhibits growth and promotes apoptosis in
glioblastoma neurospheres
We first examined the effects of ATO on the growth of
three glioblastoma neurosphere lines using the MTS
assay. In all three lines, we saw a dose dependent reduc-
tion in growth over five days (Figure 1a). These studies
were performed in technical triplicates at least 4 separate
times for each cell line with similar results, and a bar
graph containing all data points for the multiple experi-
ments is shown in the lower right panel of Figure 1a.
Mean growth inhibition of between 33-86% was seen
after treatment at the 2.5 μM ATO levels, and statis-
tically significant 65-92% inhibition of growth was
achieved by 5 μM ATO in all three neurosphere lines.
To directly determine the effects of ATO on the prolif-
eration of glioblastoma neurospheres, we assessed the
number of BRDU positive tumor cells after 72 hours of
treatment in the three lines. We identified statistically
significant reductions in proliferation of up to 90% using
2.5 uM ATO, and even more pronounced effects with
5 μM ATO (Figure 1B). These data suggest that decreased
proliferation accounts for much of the slower growth we
observed.
Induction of apoptosis may also mediate some of the
anti-tumor effects of ATO. Cleaved caspase 3 levels
were increased after ATO treatment in all three lines
tested (Figure 2A). In addition, flow cytometric analysis
revealed an increase in the sub-G1 fraction of all three
lines which was significant at higher levels of the com-
pound (Figure 2B). We also measured GFAP mRNA
levels by quantitative RT PCR, but did not detect any
increases suggesting increased glial differentiation of
tumor cells (data not shown).
ATO inhibits notch and hedgehog pathway targets
Because ATO has been reported to suppress Hedgehog
and Notch activity in other tumor types, we examined
effects on the two pathways after 24 hour treatment of
GBM neurosphere lines. Pathway activity was assessed
using quantitative RT PCR to measure levels of the ca-
nonical pathway transcriptional targets PTCH1b, GLI2
and N-Myc (Hedgehog) as well as HES1, HES5 and
HEY1 (Notch). At least two experimental replicates were
performed, each with triplicate technical measurements,
and all data points are combined in Figure 3. A statisti-
cally significant 40 – 89% inhibition of PTCH1b was
noted at the highest ATO dose in all three lines, while
the lesser 2.5 μM dose resulted in significant inhibition
in two of the three lines (Figure 3A). 2.5 μM ATO also
resulted in significant inhibition of another Hedgehog
target, N-Myc, in all three GBM lines, while the highest
ATO dose resulted in significant inhibition of two of the











Figure 1 Arsenic trioxide inhibits glioblastoma neurosphere growth and proliferation. A) MTS assays showing growth inhibition following
ATO treatment in the 040821, HSR-GBM1 and 040622 glioblastoma neurosphere lines, with a bar graph highlighting the significance compared to
vehicle. B) Representative BRDU staining images showing anti-BRDU staining (red) and DAPI counterstaining (blue) in vehicle and 5 μM ATO-treated
040622 neurosphere cells are shown in the top left panel. The percentage of BRDU positive cells in 040622, 040821 and HSR-GBM1 neurospheres was
significantly decreased in all three lines after treatment with either 2.5 μM or 5 μM ATO.
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member, GLI2, in HSR-GBM1 and 040622, while 2.5 μM
ATO resulted in significant inhibition in GBM1 and
5 μM resulted in significant inhibition in all three GBM
lines.
We also observed inhibition of Notch target expression
in GBM neurospheres treated with ATO. These changes
were not dose dependent in all the lines, but the 2.5 μM
level of ATO significantly suppressed HES5 and HEY1
in all three cultures, while the suppression of HES1 wassignificant in two of three (Figure 3B). Interestingly, the
highest levels of ATO (5 μM) resulted in an increase in
the mRNA levels of HES5 and HEY1 in several lines.
While the cause of this is not clear, we have previously ob-
served paradoxical increases in the mRNA levels of Notch
targets when treating brain tumor cells with high levels
of gamma-secretase inhibitors that target Notch, and this
may represent a feedback or resistance mechanism of
some sort in cells surviving maximal therapy (CGE,
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Figure 2 Arsenic trioxide induces apoptosis in glioblastoma neurosphere cells. A) Western blots show induction of caspase-3 cleavage in
HSR-GBM1, 040622 and 040821 cells following treatment with 2.5 μM or 5 μM ATO. B) Cell cycle analysis by flow cytometry performed on neurosphere
lines after ATO treatment reveal a significant increase in the sub-G1 population in all 3 neurosphere lines at 2.5 μM and 5 μM ATO. In 040821, there is
also a significant increase in the sub-G1 population at 1 μM ATO.
Ding et al. Acta Neuropathologica Communications 2014, 2:31 Page 5 of 10
http://www.actaneurocomms.org/content/2/1/31dose-dependent decrease of HES1 and HES5 at the
protein level, further confirming the effect of ATO on
Notch signaling (Figure 3C).Clonogenic capacity and stem cell markers are reduced
following ATO treatment
We next evaluated the effects of ATO treatment on the
clonogenic capacity of glioblastoma cells. Neurosphere
lines were treated for three days with ATO, triturated,
and counted. Equal numbers of surviving cells were then
seeded into methylcellulose and allowed to grow into
colonies with no additional treatment. We have previ-
ously shown that only large glioblastoma spheres grown
in methylcellulose can be serially passaged [45]. The
number of spheres over 100 μM in size was significantly
reduced following ATO treatment in HSR-GBM1 and
040821 cells (Figure 4), while a modest non-significant
reduction was seen in 040622 cells (data not shown).
This suggested that the stem-like clonogenic fraction is
depleted by ATO treatment.To more directly examine the effects of ATO on stem
cell markers, we measured levels of SOX2 and CD133
mRNA after 24 hours of treatment. For the HSR-GBM1
and 040622 lines, a dose-dependent significant inhibition
in CD133 mRNA expression was seen (Figure 5A, B).
Reductions in SOX2 mRNA levels were also noted in all
three lines, and were significant in 040622 (Figure 5B).
We also used flow cytometric analysis to measure the
fraction of cells expressing the marker CD133 on their
surface. Triplicate analyses showed significant reductions
in this stem-like cell fraction at both 2.5 μM and 5 μM
levels of ATO in all three lines (Figure 5C). The changes
were most pronounced in the HSR-GBM1 and 040821
lines, and relatively modest in the 040622 cells. This
experiment was repeated twice with similar results.
Discussion
Standard GBM treatment includes surgical resection
followed by radiotherapy and temozolomide (TMZ)
chemotherapy, but rarely results in long term survival








































Figure 3 Arsenic trioxide inhibits Hedgehog and Notch pathway target gene expression. A) Quantitative PCR analysis revealed that ATO
significantly inhibited transcript levels of the Hedgehog pathway target gene PTCH1b at 5 μM in all 3 glioblastoma neurosphere lines compared
to vehicle treatment, and in 2 lines after 2.5 μM ATO. ATO also significantly inhibited another Hedgehog pathway target N-Myc in 2 lines at 5 μM,
in all 3 glioblastoma neurosphere lines at 2.5 μM, and in 2 lines at 1 μM. GLI2, a 3rd Hedgehog pathway target, was significantly inhibited in all 3
lines at 5 μM ATO, in 1 line at 2.5 μM ATO, and in 2 lines at 1 μM ATO. B) ATO also significantly inhibited expression of the Notch target HES1 as
compared to vehicle treatment in HSR-GBM1 and 040622 cells, but not in 040821. HES5 and HEY1 transcript levels were also reduced in all 3
glioblastoma neurosphere lines following 2.5 μM ATO treatment, but a non-significant paradoxical increase was seen at the higher 5 μM dose.
C) ATO inhibited HES1 and HES5 protein expression in all 3 glioblastoma neurosphere lines at 5 μM, compared to vehicle treatment.
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ability to inhibit the Notch and Hedgehog pathways
which have been shown to play key roles in stem-like
glioma cells. While both of these pathways have been
shown to be inhibited by ATO in some tumor types
[47,48], the ability of this compound to affect them in
gliomas is less clear.Zhen and colleagues treated three adherent GBM lines
(U87MG, U251MG and U373MG) with ATO and re-
ported decreased protein levels of the Notch1 receptor
and HES1 target, as well as reductions in growth in vitro
and in vivo [30]. They also identified lower levels of the
stem/progenitor marker Nestin after treatment, although









Figure 4 Arsenic trioxide treatment inhibits clonogenicity in glioblastoma neurosphere cells. A) Quantification of clonogenicity in equal
numbers of single viable HSR-GBM1 and 040821 cells seeded in methylcellulose following 3 days of ATO treatment showed significantly fewer
colonies over 100 μM in size. B) Representative images of colonies.
Ding et al. Acta Neuropathologica Communications 2014, 2:31 Page 7 of 10
http://www.actaneurocomms.org/content/2/1/31good models of cancer stem cells in glioma. To our
knowledge, no data addressing the effects of ATO on
Hedgehog activity in glioma has been published.
We examined the effects of ATO inhibition on Notch
and Hedgehog pathways in three GBM neurosphere lines
which we have previously shown to contain stem-like frac-
tions that require one or both of these signaling cascades
[7,8,18]. We found that ATO inhibits growth and clono-
genicity with induction of apoptosis in all three lines.
CD133 percentage, as assessed by flow and quantitative
real-time PCR, as well as the levels of other stem celltranscripts, were also reduced following ATO treatment.
Finally, we found significant reductions in the expression
of both Notch and Hedgehog pathway targets.
A recently published study by Wu et al. [47] also ex-
amined the effects of ATO on Notch signaling and clo-
nogenic growth in several adherent GBM lines as well as
what appeared to be a single neurosphere culture [47].
Like us, they found reductions in stem cell markers and
phenotype in the glioma cells following ATO treatment,
which they suggest were at least partially due to effects
on Notch. They did not examine Hedgehog pathway
CHSR-GBM1
BA
Figure 5 Arsenic trioxide treatment inhibits the expression of stem-cell markers in glioblastoma neurosphere cells. A) A representative
experiment showing decreased transcript levels of the stem-cell marker CD133 in HSR-GBM1 cells following ATO treatment measured using
quantitative real-time PCR. B) mRNA expression of the stem-cell markers CD133 and SOX2 was suppressed by ATO. C) Flow cytometric analysis of
the CD133 positive fraction also revealed variable reductions in this stem-like subpopulation following ATO treatment. Representative flow cytometry
plots of CD133-positive cells in vehicle and ATO treated HSR-GBM1 cultures are shown in the lower right panel.
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patients, cerebrospinal fluid levels were 10-17% of those
in serum, thus local delivery may be necessary in brain
tumor patients [49,50].
In summary, ATO has been previously shown to in-
hibit the growth of high serum GBM cultures, but little
was known about its effects on glioma stem cells or the
pathways thought to promote their specification and
survival. We found that ATO depletes stem-like cancer
cells as defined by surface CD133 expression in all three
GBM neurosphere lines tested, with negative effects on
overall growth and clonogenicity. We also noted inhib-
ition of both Notch and Hedgehog signaling by ATO,
suggesting a potential mechanism for the effects on can-
cer stem cells and tumor growth. Our findings are con-
sistent with another recent study of ATO and Notch
signaling in GBM neurospheres, and together these and
prior reports support the development of ATO as a clin-
ical therapeutic agent capable of inhibiting multiple sig-
naling pathways important in stem like glioma cells.
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